ReShape Lifesciences Inc (RSLS) - Total Liabilities
Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) has total liabilities worth $3.20 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore RSLS net assets growth trend to track the company's year-over-year net asset growth rate.
ReShape Lifesciences Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc's total liabilities have evolved over time, based on quarterly financial data.
ReShape Lifesciences Inc Competitors by Total Liabilities
The table below lists competitors of ReShape Lifesciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reach Resources Ltd
AU:RR1
|
Australia | AU$471.57K |
|
Seacera Group Bhd
KLSE:7073
|
Malaysia | RM130.81 Million |
|
Micronet Ltd
TA:MCRNT
|
Israel | ILA612.00K |
|
Cinevista Limited
NSE:CINEVISTA
|
India | Rs818.69 Million |
|
WALKER RIVER RES CORP
F:1WV0
|
Germany | €562.04K |
|
Domino’s Pizza Group PLC
LSE:DOM
|
UK | GBX678.70 Million |
|
Hengli Industrial Development Group Co Ltd
SHE:000622
|
China | CN¥307.88 Million |
|
Kohinoor Foods Limited
NSE:KOHINOOR
|
India | Rs1.86 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down ReShape Lifesciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RSLS market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ReShape Lifesciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ReShape Lifesciences Inc (2003–2024)
The table below shows the annual total liabilities of ReShape Lifesciences Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.05 Million | +26.15% |
| 2023-12-31 | $4.00 Million | -46.53% |
| 2022-12-31 | $7.48 Million | -8.61% |
| 2021-12-31 | $8.19 Million | -63.74% |
| 2020-12-31 | $22.57 Million | +45.16% |
| 2019-12-31 | $15.55 Million | +6.43% |
| 2018-12-31 | $14.61 Million | +18.42% |
| 2017-12-31 | $12.34 Million | +200.78% |
| 2016-12-31 | $4.10 Million | -48.17% |
| 2015-12-31 | $7.91 Million | +2.49% |
| 2014-12-31 | $7.72 Million | -34.05% |
| 2013-12-31 | $11.71 Million | -17.66% |
| 2012-12-31 | $14.22 Million | +14.27% |
| 2011-12-31 | $12.44 Million | +38.59% |
| 2010-12-31 | $8.98 Million | -15.55% |
| 2009-12-31 | $10.63 Million | -36.98% |
| 2008-12-31 | $16.87 Million | +22.55% |
| 2007-12-31 | $13.77 Million | +83.83% |
| 2006-12-31 | $7.49 Million | -21.87% |
| 2005-12-31 | $9.59 Million | +591.15% |
| 2003-12-31 | $1.39 Million | -- |
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more